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ABSTRACT 
 
Introduction: Medicines are created with the intention of helping patients but may be harmful to 
the patient by causing adverse reactions. The effect of adverse drug reactions (ADRs) on patients 
has become more evident over the last two decades and reporting of ADRs in South Africa is low. 
This results in many patients, particularly children, potentially being exposed to medicinal 
products with an uncertain safety profile. Due to parents’ typical caring and protective role, they 
could play a part in detecting and reporting ADRs in children, thereby contributing to making safer 
medicines available to children. 
 
Aim: This research study evaluated the awareness and knowledge in South Africa of parental 
reporting of suspected ADRs in their children. 
 
Method: A quantitative descriptive study was conducted based on an anonymous web-based self-
administered questionnaire that was distributed through Facebook® and LinkedIn™ to parents in 
South Africa. The questionnaire, which was distributed between July 2018 and August 2018, was 
standardized for all participants and consisted of closed (n=28) and open-ended (n=4) questions. 
The questions were coded, data was analysed using descriptive statistics (percentage and frequency 
counts). Associations between categorical demographic variables were determined using the 
Pearson Chi-square test. 
 
Results: The questionnaire was voluntarily completed by 206 participants. Majority of the 
respondents were female (n=155, 75.2%) and the most relevant age category for all respondents 
was 31-40 years (n=100, 48.5%). The majority of participants (n=146, 70.9%) were aware of the 
term ADR and significant associations between awareness of ADRs and ethnicity, marital status, 
education level, medical aid and access to general medical services were found. Being white 
(p<0.001), having a degree (p=0.001) and having private medical aid (p=0.004) were 
independently associated with being significantly more aware of the term ADR compared to being 
black (p<0.001), coloured (p=0.004), a single parent (p=0.003), not finishing school (p<0.001), 
having matriculated (p<0.001), having no private medical aid (p=0.004) and receiving general 
medical services from public clinics (p = 0.003). 
 
More than half of the participants or their children (n=123, 59.7%) experienced an ADR. Many 
participants (n=137, 66.5%) reported an ADR to a healthcare professional while only 15% (n=31) 
reported to a product manufacturer.  The most common outcome of an ADR reported was a 
consultation with a doctor (n=74, 35.9%). It was found that 121 participants knew how to report 
ADRs and 150 participants (72.8%) knew what type of ADRs to report, however a large number 
did not know where more information on ADR reporting can be found (n=67) or how ADRs can 
be reported (n=65). Motives enhancing ADR reporting included social concerns such as helping 
others (n=48), severity of reaction (n=34) and safety concerns (n=16). Barriers deterring ADR 
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reporting included process issues (n=35), minor reaction (n=11) and no feedback/ actions being 
taken (n=9). 
 
Conclusion: Majority of the respondents were aware of the term ADR, they indicated a good 
knowledge basis on which ADRs to report and the importance of reporting ADRs.  Gaps in the 
respondents’ knowledge were identified which highlighted specific groups of individuals to be 
targeted to increase ADR awareness and improve knowledge on the reporting process. Greater 
awareness and knowledge among parents can play a considerable role in improving the safety data 
of medicines and may reduce the occurrence of ADRs in children and the general population. 
 
Keywords: Adverse drug reactions, spontaneous reporting, patient reporting systems, children, 
parental reporting, pharmacovigilance, awareness, knowledge, views, South Africa 
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CHAPTER 1: 
INTRODUCTION 
 
1.1 Introduction 
 
New medicines go through an intensive process, involving a wide-range of tests and trials, before 
being approved and released onto the market (Weigmann, 2016; Staniszewska, et al., 2017). The 
purpose of these tests is to prove the safety and efficacy of a product; however, the studies are 
usually conducted under controlled conditions with a limited number of patients for a short period 
of time (Mehta, 2011). Therefore, little is known about the safety profile of the medicine and 
unanticipated side effects are observed after approval (Weigmann, 2016). 
 
Medicines are created with the intention of helping patients, but they may be harmful to the patient 
by causing adverse reactions (van Grootheest and de Jong-van den Berg, 2004). The monitoring 
of adverse drug reactions (ADRs) to ensure patient safety is a critical component of 
pharmacovigilance (Avery, et al., 2011). Pharmacovigilance is defined by the World Health 
Organization (WHO) as “the science and activities relating to the detection, assessment, 
understanding and prevention of adverse effects or any other drug-related problem” (WHO, 2018). 
Protecting patients from the harmful effects of medicines is a responsibility that should be shared 
between all stakeholders, including healthcare professionals and patients (Suleman, 2010). 
 
1.2 Background 
 
Studies conducted throughout the world found that ADRs constitute over 6% of all hospital 
admissions and are among the leading global causes of morbidity and mortality (Gupta, et al., 
2018). ADRs result in longer hospital stays and higher costs incurred for the patient and the 
healthcare system (Wilson and Amma, 2015). Research shows that in some countries, up to 20% 
of their hospital budget is spent on managing ADRs (Mehta, 2011). 
 
A major concern is the high incidence of ADRs in children. Numerous medicines have not been 
adequately tested and approved for use in children (Napoleone, 2010). This results in off-label use 
of medicines in children which is linked to an increased risk of ADRs (Hawcutt, et al., 2011; 
Tobaiqy, et al., 2010). Pharmacovigilance is an essential component of ensuring the safe use of 
medicines in children (Napoleone, 2010). The foundation of pharmacovigilance programs is the 
reporting of ADRs spontaneously by healthcare professionals through ADR report forms (Wilson 
and Amma, 2015). Spontaneous reporting allows for unknown or uncommon reactions to be 
identified and can contribute to making safer medicines available to patients by facilitating the 
withdrawal of potentially unsafe medicines from the market (Mehta, 2011). 
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Under-reporting of ADRs has been recognized to be a common shortcoming of pharmacovigilance 
programs in South Africa as well as internationally (Wilson and Amma, 2015; Mehta, 2011). After 
reviewing the spontaneous reporting systems of 12 countries, Hazell and Shakir (2006) found that 
on average 94% of ADRs were not reported. Under-reporting prolongs the detection of ADRs and 
may result in increased death and suffering in patients (Gupta, et al., 2018). While it was found 
that healthcare professionals are aware of the need and methods to report ADRs, factors that 
prevent them from reporting include time, fear of criticism, and large amounts of patient care 
requirements (Wilson and Amma, 2015). 
 
1.3 Problem statement 
 
The effect of ADRs on healthcare professionals and patients has become more evident over the 
last two decades, yet reporting of ADRs by healthcare professionals in South Africa remains low 
(Mehta, et al., 2017). This results in many patients, particularly children, potentially being exposed 
to medicinal products with an uncertain safety profile (Mehta, 2011). Since parents have a typical 
caring and protective role, they could play a part in detecting and reporting ADRs in children. 
Parents were found to be unaware of their role in reporting ADRs in countries that have patient 
reporting systems (van Hunsel, et al., 2012). This could mean that the awareness of parental 
reporting in countries without a patient reporting system may be lower. The contribution of 
parental reporting to pharmacovigilance in South Africa could be substantial. However, parents’ 
awareness and knowledge of ADR reporting and the process involved had to first be considered. 
 
1.4 Aim and objectives 
 
The overarching aim was to evaluate the awareness and knowledge in South Africa of parental 
reporting of suspected ADRs in themselves and their children. 
 
The following research questions were investigated: 
• Are parents aware of adverse drug reactions? 
• What is the knowledge of parents on ADRs? 
• What experiences have parents had with ADRs? 
• What are the processes or steps to follow when reporting ADRs? 
• What are the views on ADR reporting? 
• Which factors may enhance or deter ADR reporting? 
 
To answer the above research questions the following primary and secondary objectives were set. 
 
1.4.1 Primary objectives 
• To assess parents’ awareness of reporting ADRs 
• To assess the knowledge of parents on the procedures to follow when reporting ADRs 
http://etd.uwc.ac.za/
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1.4.2 Secondary objectives 
• To explore parents’ views on reporting ADRs 
• To determine which factors could motivate or prevent parents from reporting ADRs 
experienced by their children or themselves 
 
1.5 Significance of the study 
 
Most of the studies in the past have evaluated ADR reporting among healthcare professionals, 
however, to the researchers’ knowledge, this was the first investigation of parental reporting in 
South Africa. Little is known about what South African parents know about ADRs or whether they 
report ADRs. There is currently no direct patient reporting system in South Africa, therefore this 
evaluation of the awareness and knowledge of reporting ADRs by parents can be useful to the 
regulatory authorities and pharmaceutical applicants, who may consider implementing a formal 
patient reporting system in future. 
 
This study highlighted challenges to reporting ADRs and possible recommendations to overcome 
it. It has contributed to identifying gaps and how to address it to improve parents’ knowledge on 
ADR reporting and generate awareness among parents as to the importance of reporting. It may 
have also improved adult patients’ understanding of what ADRs are, who they need to be reported 
to and why they need to be reported. The public may have been made aware of the valuable 
contribution that they can make to safe medicine use.  
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CHAPTER 2: 
LITERATURE REVIEW 
 
2.1 Introduction 
 
This chapter reviews and discusses pertinent literature that is relevant to this study. 
 
The WHO defines an ADR as “a response to a drug which is noxious, and unintended, and which 
occurs at doses normally used in man for prophylaxis, diagnosis or therapy of disease, or for the 
modification of physiological function” (WHO, 2002, p.5). While sometimes confused with an 
ADR, an adverse event refers to an untoward experience associated with the use of a drug, but 
which is not necessarily caused by the drug and a side effect refers to an unintended effect of a 
drug which is related to its pharmacological properties and occurs at normal doses (WHO, 2002). 
 
Research has revealed that ADRs have become a universal public health matter that may need to 
be addressed using a different approach (Mehta, 2011). Spontaneous reporting by patients is one 
of the methods that is increasingly being utilized. Patient reporting systems have existed in many 
countries, including the United States of America (USA), Canada, Australia, the Netherlands, 
Italy, Sweden, the United Kingdom (UK) and more recently Norway (Wilson and Amma, 2015). 
Patient reporting systems were introduced in European Union (EU) legislation to improve 
medicine safety and has been seen as a valuable contribution to protecting public health (Rolfes, 
et al., 2014). 
 
As medicines are intended to benefit patients, obtaining information directly from patients plays a 
key role in identifying new ADRs (Weigmann, 2016). Research has shown that patients worldwide 
have substantial interest in the safety aspects of medicines and allowing them to report ADRs has 
offered a unique approach to pharmacovigilance (van Grootheest and de Jong-van den Berg, 2004).  
 
2.2 International practices on reporting by patients 
 
Many countries allow patient reporting through existing systems for healthcare professionals or a 
system designed specifically for non-healthcare professionals (Matos, et al., 2016). Patients in the 
UK submit ADR reports to the Medicines and Healthcare Products Regulatory Agency (MHRA), 
through the Yellow Card System (YCS) (Anderson, et al., 2011). Within five years after patient 
reporting systems were introduced in the UK, 18% of the ADRs were reported by patients 
(Fortnum, et al., 2012). Patients in the USA have been reporting ADRs for many years using the 
MedWatch program (Avery, et al., 2011). In both the UK and USA, the reporting process for 
patients is the same as that for healthcare professionals (Avery, et al., 2011). Studies, however, 
have shown differences between the reports submitted by patients and healthcare professionals 
(Avery, et al., 2011). Patient reports contained more subjective information, in terms of the impact 
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of the ADR on their lives, whereas reports from healthcare professionals contained more objective 
information, such as route of administration of the drug and patient medical history (Rolfes, et al., 
2015). 
 
The Adverse Drug Reactions Unit (ADRU), which forms part of the Therapeutic Goods 
Administration (TGA) is available for patients in Australia to report ADRs (Avery, et al., 2011). 
A study conducted by Avery, et al. (2011) found that a large number of serious ADRs reported by 
patients in Australia were not reported by healthcare professionals. Patients in Canada can report 
ADRs to the Canadian Adverse Drug Reaction Monitoring Program (CADRMP) and patients in 
the Netherlands report to the Netherlands Pharmacovigilance Center (Lareb) (Avery, et al., 2011). 
A downside to the Lareb system is that patients can only submit electronic reports which may have 
impeded patients from reporting, due to insufficient internet access (Avery, et al., 2011). 
 
In Ghana, although ADR reports were always accepted from patients, ADRs have primarily been 
reported by healthcare professionals (Sabblah, et al, 2017). A patient reporting system was 
launched in 2016, in which patients can report ADRs, through the Blue Form, to the National 
Pharmacovigilance Centre, which is part of the Ghana Food and Drugs Authority (FDA) (Darko 
and Sabblah, 2015). In Saudi Arabia, ADR reports can be submitted to the NPC by healthcare 
professionals, pharmaceutical manufacturers and patients from 2009 (Sales, et al., 2017). Patients 
in Poland, on the other hand, were only able to report ADRs to the Department for Monitoring 
Adverse Reactions of Medicinal Products, with an online system being introduced in 2015 for 
reporting of ADRs through the patients’ smartphones (Staniszewska, et al., 2017). 
 
Spontaneous reporting of ADRs has been present in Croatia since 1974, with patients being able 
to report ADRs to the Agency of Medicinal Products and Medical Devices, called HALMED, from 
2009. Croatia was one of the first countries to introduce an online system for patients to report 
ADRs using their mobile devices (Glamočlija, et al., 2018). Despite various countries having 
introduced patient reporting systems, there are still numerous countries that do not have systems 
in place for direct patient reporting of ADRs (Sales, et al., 2017). 
 
2.2.1 Potential benefits of patient reporting 
 
Global studies have indicated that patient reports of ADRs provide supplemental information to 
the reports submitted by healthcare professionals because of the different point of view of the 
patient (Wilson and Amma, 2015; van Hunsel, et al., 2012). Patient reporting systems have given 
the public the opportunity to be more involved in their own care and has improved reporting of 
ADRs on over-the-counter (OTC) products, which physicians are unlikely to report (Avery, et al., 
2011; Wilson and Amma, 2015). Reports from patients were found to be more detailed, in terms 
of the ADR description and the influence on the patient’s life, and free of bias due to lack of 
medical expertise (Wilson and Amma, 2015; Rolfes, et al., 2014). As the report comes directly 
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from the person who has experienced the ADR, the description was found to be more accurate 
(Herxheimer, et al., 2010). Research also found that patients may report adverse effects sooner 
than healthcare professionals would (Lebanova and Getov, 2014).  
 
Patients are sometimes hesitant to mention to healthcare professionals the array of medicines that 
they are taking, or the unusual effects that they experience (Mehta, 2011). By reporting to a person 
or authority that is not familiar with the patient, the patient may be less reluctant to provide this 
important information. Patients also may not report to healthcare professionals because of a belief 
that the healthcare professional will not do anything about it (Blenkinsopp, et al., 2006). The ability 
to report immediately may empower the patient to speak up about his/her concern which could 
prevent further harm to the patient by identifying and managing the ADR timeously (Mehta, 2011).  
 
Children are known to have a higher risk of experiencing ADRs compared to adults and because 
they are often not able to verbally express their experiences, the monitoring and reporting of ADRs 
by parents is important (Hawcutt, et al., 2011). Evidence suggests that parental reporting provides 
several benefits for pharmacovigilance, including increasing the rate of reporting of ADRs and 
identifying previously unknown ADRs in children (Oshikoya, et al., 2009). This leads to an 
increase in safety data available and ultimately assists in providing quality health care to children 
(Napoleone, 2010; Oshikoya, et al., 2009). 
 
2.2.2 Concerns about patient reporting 
 
Evidence has suggested that patient reports may help identify new ADRs, however, few studies 
have investigated the impact of patient reports on pharmacovigilance (Avery, et al., 2011). There 
have been concerns by regulatory authorities about receiving reports from patients that are not 
serious or are of low quality (Blenkinsopp, et al., 2006). Contrary to expectations, the quality of 
reports received from patients has been of good quality globally (Matos, et al., 2016; Pahuja, et 
al.,  2014). There have also been concerns regarding the difference in opinions between patients 
and healthcare professionals about the seriousness of an ADR or determining whether the adverse 
reaction was likely caused by the medicine or a disease (Blenkinsopp, et al., 2006). In Norway, 
patient reports are not assessed for causality, whereas in Australia, causality is assessed for all 
serious adverse reactions (van Hunsel, et al., 2012). Seriousness is assessed by most countries 
using the Council for International Organizations of Medical Sciences (CIOMs) committee criteria 
and causality is often assessed using the WHO causality assessment model, which takes into 
account the clinical-pharmacological attributes of the case history and the quality of the report (van 
Hunsel, et al., 2012; WHO-UMC (undated)).  
 
Another apprehension of encouraging patients to report was that influence from the media may 
result in unnecessary events being reported or it may result in patients discontinuing their treatment 
inappropriately (Herxheimer, et al., 2010). Nevertheless, it has been noted that the patient is able 
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to provide a clearer description than the healthcare professional of how the ADR affected the 
patient’s life, family and job (Sales, et al., 2017). Experiences from European countries favour 
patient reporting but indicates that additional information from healthcare professionals may be 
required for a better understanding of the ADRs (Rolfes, et al., 2014). A study revealed that patient 
reporting in Ghana has also shown positivity, while studies show low patient reporting in other 
developing countries (Sabblah, et al., 2017; Inácio, et al., 2017).  
 
2.2.3 Patient awareness of reporting 
 
While it is evident that patients can offer useful input to pharmacovigilance programs, there are 
factors which prevent patients from reporting (Lebanova and Getov, 2014). Poor economic status, 
resulting in the inability to post reports or access the internet to submit reports electronically, has 
been found to deter ADR reporting by patients in developing countries (Dweik, et al., 2017). 
Another reason for patients not reporting ADRs is a lack of awareness (Matos, et al., 2016). 
Raising public awareness of the need to report, what to report as well as how and to whom to report 
may increase the number of reports from patients (Weigmann, 2016). 
 
Increasing publicity of patient reporting, simplifying patient reporting systems and allowing 
patient reports to be submitted through a variety of methods (e.g. telephone, email, post), could 
enhance the timeliness and value of patient reporting (van Hunsel, et al., 2012). An aspect of 
increasing publicity is to inform healthcare professionals about the benefits of patient reporting 
(Avery, et al., 2011). 
 
2.3 Reporting in South Africa 
 
Patient reporting is not actively promoted in many countries due to financial limits and a lack of 
resources (Matos, et al., 2016). In South Africa, a spontaneous reporting system is used, in which 
healthcare providers are responsible for reporting suspected ADRs to the National Adverse Drug 
Event Monitoring Centre (NADEMC), a unit of the South African Health Products Regulatory 
Authority (SAHPRA), formerly known as the Medicines Control Council (MCC) (Mehta, et al., 
2017; Maigetter, et al., 2015). NADEMC was established by the South African National 
Department of Health (NDOH) and is coordinated by the National Pharmacovigilance Centre 
(NPC) (Mehta, 2011; Dheda, 2016). Figure 1 shows the flow of ADR information to the NPC and 
the safety information generated and sent back to the reporters (Dheda, 2016). 
 
There is currently no system in place for patients to report suspected ADRs directly to the 
NADEMC, but they can report to pharmaceutical manufacturers, either telephonically or via the 
company website (Mehta, et al., 2017). Pharmaceutical companies work closely with NADEMC 
to ensure that the regulatory authority is informed about ADRs experienced by patients in South 
Africa (Maigetter, et al., 2015). 
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Figure 1: Pharmacovigilance system in South Africa (Taken from Dheda, 2016)  
 
2.4 Parental reporting 
 
In comparison to reporting by adult patients, studies evaluating the reporting of ADRs by parents 
are limited (Hawcutt, et al., 2011). Self-medicating is a common practice in developing countries 
due to high costs of private healthcare and poor quality of public healthcare (Oshikoya, et al., 
2009). Parental self-medication, in combination with off-label use of medicines have increased the 
risk of ADRs in children (Hawcutt, et al., 2011). 
 
Research has found that, in countries with patient reporting systems (e.g. UK, India, Malaysia), 
parents were not aware of their role in reporting ADRs (Fortnum, et al., 2012; Joshi, et al., 2015). 
Findings from a study conducted by Anderson, et al., (2011) indicate that the majority of patients 
who reported ADRs had altruistic motives while only a small number reported for personal benefit. 
Altruistic motives included preventing others from experiencing a similar reaction and improving 
medicine safety. Studies indicated that reasons for some parents not reporting is that they did not 
consider it their responsibility to report ADRs or they felt that their reports would be of little value 
due to lack of medical knowledge. Other parents were optimistic about reporting but were 
uncertain about who should report ADRs and what type of ADRs to report (Arnott, et al., 2012).  
 
Although reporting by parents has shown to be beneficial in helping to identify ADRs previously 
unknown in children and has the potential to strengthen existing pharmacovigilance programs, 
parental reporting globally is not frequent (Pahuja, et al., 2014; Oshikoya, et al., 2009; Hawcutt, 
et al., 2011). If the awareness that parents can report suspected ADRs in their children is low in 
countries where a patient reporting system exists, the awareness of parental reporting in countries 
without a patient reporting system may be even lower. This leads to the question of what the 
awareness and knowledge of parental reporting of ADRs in South Africa is.  
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CHAPTER 3: 
METHODOLOGY 
 
3.1 Introduction 
 
This chapter presents the methodology of the study by discussing the setting, study design, 
population, data collection and analysis, validation of research tool and the ethical considerations. 
A survey refers to the process of collecting information from a sample of individuals through 
various methods to make an inference about the larger population (Ponto, 2015). A questionnaire 
is one method of obtaining information through either open or closed-ended questions or a 
combination of both (Boynton and Greenhalgh, 2004). 
 
3.2 Study design 
 
A quantitative descriptive study was used to conduct a survey, which was based on an anonymous 
questionnaire provided to participants to self-complete to assess their awareness and knowledge 
of reporting ADRs. See Appendix 2 - Questionnaire. 
 
The questionnaire comprised of three sections that covered: 
• Demographic information,  
• Adverse drug reaction awareness and knowledge, and  
• Views on adverse drug reaction reporting. 
 
It consisted of 28 closed-ended questions with multiple choice (n=23) and Likert-type options, 
(n=5) as well as four open-ended questions where the respondents could type in their own 
feedback. Although the methodology was primarily quantitative, the open-ended questions (D6, 
D8, E3 and E4) generated qualitative data where main themes were identified by the researchers. 
The results of these open-ended questions, however, were reflected as frequency counts 
(quantitative). 
 
Knowledge level was determined by who should report ADRs, who to report ADRs to and what 
type of ADRs to report. 
 
3.3  Study population 
 
The survey was conducted on parents living in South Africa who voluntarily responded to the 
posted online questionnaire. 
 
Inclusion criteria: 
• Parents over the age of 18 years living in South Africa 
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• Male and female parents 
• Parents of adopted children 
• Parents of step children 
• Parents of children (< 18 years) 
• Parents that can read and understand English 
 
Exclusion criteria:  
• Minors (under the age of 18 years) 
• Adults who do not have any children 
• South African parents living abroad 
 
3.4 Data collection 
 
A web-based self-administered questionnaire (research instrument) was constructed and 
distributed through Google Forms to parents in South Africa. The link to the questionnaire was 
distributed on social media platforms, such as Facebook® and LinkedIn™ for a period of 9 weeks, 
from July 2018 to August 2018.  
 
The benefits of using social media include low costs, a diverse target population and the possibility 
of the questionnaire being shared to additional individuals (Bethlehem, 2010; Wright, 2005). 
Respondents were encouraged to share the questionnaire with potential participants in their social 
media community. A negative aspect of distributing the survey on social media was the possibility 
of the results being skewed due to self-selection bias. This type of bias occurs when individuals 
are entrusted to select themselves for the survey and usually decide to participate because of their 
own interest in the topic (Bethlehem, 2010). 
 
Potential participants were required to answer the question “Do you have any children” to exclude 
non-parents from answering the remaining questions. 
 
3.4.1 Reliability and validity of research tool 
 
The research instrument (questionnaire) was validated by measuring and identifying the number 
of systematic or built-in errors in the questionnaire (Van Tilburg Norland, 1990). It determined 
whether the indicators used described the meaning of the theory that the researcher was testing. 
There are four different types of validity according to Neuman (2014):  
• Face validity  
• Content validity  
• Construct validity  
• Criterion validity  
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Face and content validity were used in this investigation. The primary researcher and the student 
researcher, together with colleagues and subject matter experts were involved in the questionnaire 
design to ensure face and content validity (Kelley, et al., 2003). 
 
The questionnaire was designed and developed based on existing questionnaires on the same 
subject matter and after existing literature was reviewed and examined (Joshi, et al., 2015; Pahuja, 
et al., 2014; Sales, et al., 2017; Staniszewska, et al., 2017). The researchers reviewed the relevance 
of each main category and respective questions in relation to the set objectives. 
 
The questionnaire was standardized for all participants to ensure reliability and was based on good 
writing and language principles to ensure that the questionnaire was clear and easy to understand 
and that the sequences of questions were easy to follow (Neuman, 2014; Kumar 2014). 
 
3.4.2 Pilot study 
 
The questionnaire was piloted before implementation by administering it to five volunteers who 
were similar to the target population and who were not included in the principal study (van 
Teijlingen and Hundley, 2001). Participants of the pilot study were requested to record the time it 
took to complete the questionnaire and provide any feedback or comments on the questionnaire. 
 
The pilot study assisted in identifying potential problems with the structure and understandability 
of the questionnaire, thereby establishing questionnaire validity. The pilot study identified minor 
changes to be made to the informed consent and questionnaire. The informed consent was amended 
to include "dear potential participant" and the expected duration of the questionnaire was reduced 
from 20 to 15 minutes. 
 
3.5 Data analysis 
 
The questions were coded, and the data collected was entered and cleaned in Microsoft Office 
Excel (2016). To ensure that the data was of high quality, quality control activities were performed 
on the database. To confirm that the coding was done correctly, a proportion (20%) of the data was 
cross-checked. 
 
Data was analysed using IBM® SPSS® Statistics software, version 23. Descriptive statistics were 
used, and the data was summarized using percentages, frequency tables, bar charts and cross 
tabulations. Where more than one option could have been chosen, only the frequency counts were 
used in the tables and figures. Associations between categorical variables were determined using 
the Pearson Chi-square test and differences were considered statistically significant if the p-value 
(α) was <0.05. Adjusted p-values (Bonferroni correction) were calculated for multiple 
comparisons (e.g. Ethnicity: Black; Coloured; Indian; White). For each of the multiple 
http://etd.uwc.ac.za/
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comparisons, the critical p –value (α) in this study (0.05) was then divided by the number of 
comparisons being made to set a new stricter significant threshold level as a post-hoc test for 
probability to control possible false positives and negatives (Haynes, 2013).  
 
Thematic analysis was performed on open-ended questions (Questions D6, E3 and E4) to identify 
themes within the data (Maguire and Delahunt, 2017). This process involved reviewing the data, 
generating initial codes, searching for themes, reviewing the themes then defining and naming the 
themes accordingly (Clarke and Braun, 2013). Consensus on the various themes was performed 
by both the primary researcher and the student researcher. 
 
The patients’ descriptions of the various ADRs experienced (Question D8) were linked to different 
organ systems. Each ADR was classified according to the WHO system organ classification (SOC) 
(WHO, 2011). The list of SOCs in alphabetical order is presented in Table 1. Fever was linked to 
the general disorders and administration site conditions and non-specific allergic reactions were 
linked to the immune system (WHO, 2011). 
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Table 1: The Medical Dictionary for Regulatory Activities (MedDRA) Terminology System 
Organ Classification List 
SOC Blood and lymphatic system disorders  
SOC Cardiac disorders  
SOC Congenital, familial and genetic disorders  
SOC Ear and labyrinth disorders  
SOC Endocrine disorders  
SOC Eye disorders  
SOC Gastrointestinal disorders  
SOC General disorders and administration site conditions  
SOC Hepatobiliary disorders  
SOC Immune system disorders  
SOC Infections and infestations  
SOC Injury, poisoning and procedural complications  
SOC Investigations  
SOC Metabolism and nutrition disorders  
SOC Musculoskeletal and connective tissue disorders  
SOC Neoplasms benign, malignant and unspecified (incl. cysts and polyps)  
SOC Nervous system disorders  
SOC Pregnancy, puerperium and perinatal conditions  
SOC Psychiatric disorders  
SOC Renal and urinary disorders  
SOC Reproductive system and breast disorders  
SOC Respiratory, thoracic and mediastinal disorders  
SOC Skin and subcutaneous tissue disorders  
SOC Social circumstances  
SOC Surgical and medical procedures  
SOC Vascular disorders  
Taken from WHO, 2011 
 
3.6 Ethical considerations 
 
All participants were provided with a concise online information sheet indicating the purpose of 
the research and describing any risk and/or benefit to them. Potential participants were given the 
option to participate in the research project and contact details to ask any questions that they had. 
Participants were informed that they may decline to answer any of the questions, without any 
reason or penalty.  
 
http://etd.uwc.ac.za/
14 
 
Participants were included in the research based on an informed consent process. A consent form 
was drawn up and consent was obtained from each participant before participating in the study. 
See Appendix 1 - Participant Informed Consent and Informational Sheet. Participants were not 
allowed to continue to the questionnaire unless they had selected “agree” to the statement “the 
study has been explained to me in a language that I understand, and I freely and voluntarily agree 
to participate”, which served as the participant’s consent to participate in the study. If participants 
selected “disagree” they were taken to the end of the questionnaire and were not able to answer 
any of the other questions. 
 
Care was taken to respect participant’s privacy and ensure confidentiality. An online survey tool 
(Google Forms) was used to deliver the questionnaire to maintain anonymity. No traceability back 
to the respondents was possible via email address. The electronic filled questionnaires were saved 
on a password protected database and the information was not used for any other purpose apart 
from the purpose of this study. 
 
The study was approved by the Biomedical Science Research Ethics Committee of the University 
of the Western Cape on 8 June 2018 (Reference Number: BM/18/4/5). 
 
3.7 Timeline 
 
The research project, inclusive of proposal writing, data collection, data analysis and writing of 
the final report, was conducted between February 2018 and December 2018. 
 
3.8 Budget 
 
No budget was required to perform this study as data was recorded electronically. 
http://etd.uwc.ac.za/
15 
 
CHAPTER 4: 
RESULTS 
 
4.1 Introduction 
 
This chapter presents the findings of this study in a descriptive format (frequencies and 
percentage). The results cover socio-demographic characteristics and are presented according to 
the research questions posed. Associations were also made between the demographics of the 
respondents and their awareness of the term ADR. 
 
4.2 Socio-demographics 
 
A total of 206 parents completed the questionnaire. The detailed socio-demographics of the 
respondents are summarized in Table 2. 
 
Overall, 75.2% (n=155) of the participants were female, 24.3% (n=50) were male and 0.5% (n=1) 
did not respond to the question regarding gender. There was representation from each of the nine 
provinces, although the majority (n=141, 68.4%) of the respondents were from Gauteng. 
 
The majority (n=100, 48.5%) of the respondents were in the age category 31-40 years and from 
White (n=89, 43.2%) and Indian (n=77, 37.4%) ethnicity. The marital status of respondents was 
reported as married by 73.8% (n=152) of respondents and 45.6% (n=94) reported having two 
children. 
 
Most of the participants indicated that they have a degree (n=75, 36.4%), with the highest level of 
education reported as a master’s degree. Primary area of employment was diverse with healthcare 
(n=40, 19.4%) being reported the most, followed by education and training (n=35, 17%) and 
financial services (n=35, 17%). The greater part of respondents had private medical aid (n=177, 
85.9%) and made use of private physicians (n=177, 85.9%) for their general medical services. 
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Table 2: Socio-demographic characteristics of participants 
Characteristic Number of Participants (%) 
Gender                                         Male 
                                            Female 
50 (24.3%) 
155 (75.2%) 
Age                                               18-30 
                                                      31-40 
                                                      41-50 
                                                      >50 
33 (16.0%) 
100 (48.5%) 
60 (29.1%) 
13 (6.3%) 
Ethnicity                                      Black 
                                                      Coloured 
                                                      Indian 
                                                      White 
32 (15.5%) 
8 (3.9%) 
77 (37.4%) 
89 (43.2%) 
Province                                       Eastern Cape 
                                                      Free State 
                                                      Gauteng 
                                                      Kwazulu-Natal 
                                                      Limpopo 
                                                      Mpumalanga 
                                                      North West 
                                                      Northern Cape 
                                                      Western Cape 
12 (5.8%) 
6 (2.9%) 
141 (68.4%) 
14 (6.8%) 
5 (2.4%) 
4 (1.9%) 
4 (1.9%) 
3 (1.5%) 
17 (8.3%) 
Marital Status                             Single 
                                                      Married 
                                                      Divorced 
                                                      Separated 
                                                      Widowed 
26 (12.6%) 
152 (73.8%) 
20 (9.7%) 
6 (2.9%) 
2 (1.0%) 
Number of Children                   1 
                                                      2 
                                                      3 
                                                      4 or more 
59 (28.6%) 
94 (45.6%) 
35 (17.0%) 
18 (8.7%) 
Highest Level of Education        Did not finish school 
                                                      Matric certificate 
                                                      Diploma 
                                                      Degree 
                                                      Other 
6 (2.9%) 
41 (19.9%) 
68 (33.0%) 
75 (36.4%) 
15 (7.3%) 
Primary Area of Employment   Student 
                                                      Unemployed 
                                                      Automotive industry 
                                                      Education and training 
                                                      Financial services 
                                                      Healthcare 
                                                      Information technology 
                                                      Legal services 
                                                      Wholesale and retail trade 
                                                      Other 
3 (1.5%) 
11 (5.3%) 
15 (7.3%) 
35 (17.0%) 
35 (17.0%) 
40 (19.4%) 
10 (4.9%) 
8 (3.9%) 
9 (4.4%) 
32 (15.5%) 
Medical Aid                                 Yes 
                                                      No 
177 (85.9%) 
29 (14.1%) 
General Medical Services          Private doctor 
                                                      Private nurse 
                                                      Pharmacy 
                                                      Public clinic 
177 (85.9%) 
1 (0.5%) 
15 (7.3%) 
12 (5.8%) 
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4.3 Adverse drug reaction awareness and knowledge 
 
The research questions that were investigated in this section include: 
• Are parents aware of adverse drug reactions? 
• What is the knowledge of parents on ADRs? 
• What experiences have parents had with ADRs? 
• What are the processes or steps to follow when reporting ADRs? 
 
One of the objectives of the study was to assess parents’ awareness of reporting ADRs and another 
objective was to assess their knowledge on the procedures to follow when reporting ADRs. This 
was measured in terms of their awareness of the term ADR, their awareness of identifying an ADR 
and their knowledge of who should report ADRs, who to report ADRs to, what type of ADRs to 
report and how to report ADRs.  
 
According to Figure 2, 70.9% (n=146) of the participants were aware of the term ADR before 
completing the questionnaire, while 29.1% (n=60) were not aware.  
 
 
Figure 2: Participants’ awareness of the term ‘adverse drug reaction’ 
 
Although many of the respondents were aware of the term ADR prior to taking part in this 
investigation, it was important to see if certain socio-demographic factors could have played a role 
in this awareness more than others. The associations between certain socio-demographic variables 
and awareness of the term ADR are illustrated in Table 3.  
 
Aware
Not aware
60 
(29.1%)
146 
(70.9%) 
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Table 3: Association between different socio-demographic variables and awareness of the 
term ‘adverse drug reaction’ 
Socio-demographic 
variables 
Aware  
(Yes) 
Not aware 
(No) 
Pearson Chi-
Square 
Adjusted p-value 
(Bonferroni correction) 
ETHNICITY –                             Threshold significance level when p < 0.006 for multiple comparisons 
Black 13 (40.6%) 19 (59.4%) 16.8 < 0.001* 
Coloured  2 (25%) 6 (75%) 8.5 0.004* 
Indian 56 (72.7%) 21 (27.3%) 0.2 0.651 
White 75 (84.3%) 14 (15.7%) 13.6 <0.001* 
MARITAL STATUS -                 Threshold significance level when p < 0.005 for multiple comparisons 
Single 12 (46.2%) 14 (53.8%) 8.8 0.003* 
Married 113 (74.3%) 39 (25.7%) 3.4 0.066 
Divorced 15 (75%) 5 (25%) 0.2 0.669 
Separated 4 (33.3%) 2 (33.3%) 0.1 0.818 
EDUCATION LEVEL -              Threshold significance level when p < 0.005 for multiple comparisons 
Did not finish school 0 (0.0% 6 (100.0%) 15.3 < 0.001* 
Matric certificate 18 (43.9%) 23 (56.1%) 18.7 < 0.001* 
Diploma 50 (73.5%) 18 (26.5%) 0.3 0.607 
Degree 64 (85.3%) 11 (14.7%) 11.5 0.001* 
Other 14 (93.3%) 1 (6.7%) 3.9 0.050 
EMPLOYMENT AREA -           Threshold significance level when p < 0.003 for multiple comparisons 
Student 1 (33.3%) 2 (66.7%) 2.1 0.144 
Unemployed 5 (54.5%) 5 (45.5%) 1.6 0.209 
Automotive Industry 7 (46.7%) 8 (53.3%) 4.8 0.030                             ns 
Education and training 29 (82.9%) 6 (17.1%) 2.8 0.094 
Financial services 27 (77.1%) 8 (22.9%) 0.7 0.393 
Healthcare 36 (90.0%) 4 (10.0%) 8.6 0.003                             ns 
Information technology 7 (70.0%) 3 (30.0%) 0.01 0.931 
Legal services 6 (75.0%) 2 (25.0%) 0.1 0.809 
Wholesale and retail trade 3 (33.3%) 6 (66.7%) 6.6 0.01                               ns 
Other 19 (59.4%) 13 (40.6%) 2.6 0.106 
MEDICAL AID -                          Threshold significance level when p < 0.013 for multiple comparisons 
Medical aid 132 (74.6%) 45 (25.4%) 8.3 0.004* 
No medical aid 14 (48.3%) 15 (51.7%) 8.3 0.004* 
ACCESS TO GENERAL MEDICAL SERVICES -        Threshold significance level when p < 0.006                  
                                                                                               for multiple comparisons 
Private doctor 131 (74.0%) 46 (26.0%) 6.7 0.009                             ns 
Private nurse 1 (100.0%) 0 (0.0%) 0.4 0.519 
Pharmacy 10 (66.7%) 5 (33.3%) 0.1 0.719 
Public clinic 3 (25.0%) 9 (75.0%) 12.9 0.003* 
*statistically significant 
ns – not significant according to the new set threshold significance level for multiple comparisons 
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A large proportion of black (59.4%, p–value<0.001) and coloured (75%, p-value=0.004) 
participants were significantly associated with not being aware of the term ADR, while a large 
proportion of white participants (84.3%, p–value < 0.001) were significantly associated with being 
aware of the term ADR. Being Indian indicated no association with the term ADR.  
 
Within the marital status multiple comparison, a large proportion of single participants (53.8%, p-
value=0.003) were significantly associated with not being aware of the term ADR. All other 
marital statuses showed no association with the term ADR. 
 
Having a degree was significantly associated with a high proportion of participants being aware of 
the ADR term (85.3%, p–value<0.001), whereas having matriculated (56.1%, p–value<0.001) and 
not finishing school (100%, p–value<0.001) were significantly associated with a high proportion 
of participants not being aware of the ADR term. 
 
After adjusting for multiple comparisons, it was found that none of the various employment 
categories had any association with awareness of the term ADR.  
 
Having a medical aid was significantly associated with a high proportion of participants who were 
aware of the term ADR (74.6%, p–value=0.004) and having no medical aid was significantly 
associated with a high proportion of participants who were not aware of the term ADR (51.7%, p–
value=0.004). Receiving general medical services from a public clinic was significantly associated 
with a high proportion of participants who were not aware of the term ADR (75%, p-value=0.003) 
 
More specific knowledge of respondents on ADRs are reflected in Table 4, many participants 
recognised that ADRs can harm people of all ages (n=150), all medicines can cause ADRs (n=130) 
and that the collection of information on ADRs contributes to improving patient safety (n=189, 
91.7%). 
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Table 4: Participants’ knowledge of adverse drug reactions 
Question Responses Frequency 
Which age group can be harmed 
from ADRs? # 
Children 45 
Adults 21 
Elderly 23 
All ages 150 
I do not know 12 
No response to question 1 
What type of medication can 
cause ADRs? # 
New medicines 35 
OTC medicines 47 
Complementary medicines (traditional, herbal, etc.) 16 
All medicines 130 
Does the collection of information 
on ADRs contribute to improving 
patient safety? 
Yes 189  
No 14  
No response to question 3  
# More than one option could have been indicated 
 
According to Figure 3, 59.7% (2.9% + 3.9% + 26.2% + 26.7%) (n=123) of the participants and/or 
their children experienced an ADR and 40.3% (n=83) indicated that neither they nor their children 
had experienced an ADR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Adverse drug reactions experienced by participants and/or their children 
 
 
http://etd.uwc.ac.za/
21 
 
Figure 4 presents how the participants became aware of the ADR experienced. Several participants 
(n=100, 48.5%) stated that they became aware of the ADR due to a physical reaction that was 
observed, while others indicated that they knew it was an ADR due to an experience from the past 
(n=2, 1.0%), information from others (n=2, 1.0%) or a forewarning from a healthcare professional 
(n=3, 1.5%). 
 
Responses such as “I read [the] info pamphlet inside [the] pill case” and “[I] studied nursing so [I 
was] aware from an early age” were categorized as miscellaneous. A considerable number (n=43, 
20.9%) of respondents indicated that the question “how did you become aware that you or your 
child may be experiencing an ADR” was not applicable, while others (n=50, 24.3%) did not answer 
the question. 
 
 
Figure 4: How participants became aware of the adverse drug reaction experienced 
 
Table 5 represents ADRs as described by the respondents, classified according to the WHO SOC. 
The skin was found to be the most commonly affected organ system (n=22, 23.9%), followed by 
the gastrointestinal (n=20, 21.7%) and immune (n=16, 17.4%) systems. 
 
 
 
Physical reaction observed
Experience from past
Information from others
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No response to question
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http://etd.uwc.ac.za/
22 
 
Table 5: Adverse drug reactions classed according to system organ classification  
Organ system Frequency Percentage 
Cardiac disorders 2 2.2% 
Ear and labyrinth disorders 2 2.2% 
Gastrointestinal disorders 20 21.7% 
General disorders and administration site conditions 5 5.4% 
Immune system disorders 16 17.4% 
Musculoskeletal and connective tissue disorders 1 1.1% 
Nervous system disorders 13 14.1% 
Psychiatric disorders 4 4.3% 
Renal and urinary disorders 1 1.1% 
Respiratory, thoracic and mediastinal disorders 6 6.5% 
Skin and subcutaneous tissue disorders 22 23.9% 
No ADR stated / no response to question 
Total 
114 
206 
55.3% 
100.0% 
 
The most common outcome of an ADR described was a consultation with a doctor (n=74, 35.9%), 
followed by ADR resolved on its own (n=55, 26.7%) and admission to hospital (n=17, 8.3%). A 
few of the respondents indicated that a visit to the clinic was necessary (n=5, 2.4% and even less 
indicated that the ADR resulted in a prolonged hospital stay (n=2, 1.0%) The outcomes are 
depicted by Figure 5. 
 
Figure 5: Outcome of one of the adverse drug reactions experienced 
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Figure 6 presents the reporting of ADRs by participants to healthcare professionals and product 
manufacturers (pharmaceutical applicants). A third of parents (n=69, 33.5%) never informed a 
healthcare professional about an ADR experienced by themselves or their child and most parents 
(n=175, 85%) never informed the product manufacturer about their ADR encounter. 
 
Figure 6: Reporting to healthcare professionals and product manufacturers 
 
Table 6 presents frequency counts (more than one option could have been selected) to questions 
regarding the ADR reporting process. A pharmacy was the selection for approximately half of the 
respondents (n=114) with the remaining selections being a doctor’s surgery (n=90), a 
pharmaceutical company (n=83) and a hospital (n=73). A small number of participants believed 
that only healthcare professionals should report ADRs (n=32), similar to those that believed that 
only patients should report ADRs (n=30). However, the majority (n=138) believed that reporting 
ADRs is both the responsibility of healthcare professionals and patients.  
 
Regarding to whom ADRs can be reported, a large number (n=183) of participants selected product 
manufacturers, 165 selected NADEMC, 154 selected doctors, 136 selected pharmacists and 104 
indicated that ADRs should be reported to nurses. It was surprising to note that more than half 
(n=121) of the respondents had knowledge of how to report ADRs (by post, telephone, 
email/website), while 19 respondents were incorrect (only be post/ only by telephone/ only by 
email/website) and 65 respondents indicated that they did not know how to report ADRs. The 
responses to the questions regarding the ADR reporting process can be seen in Table 6. 
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Table 6: Participants’ responses regarding the reporting process or steps to be taken  
Question Responses Frequency 
Where can you find more 
information on ADR 
reporting?# 
From a hospital 73 
From a pharmacy 114 
From a doctor’s surgery 90 
From a pharmaceutical company 83 
I do not know 67 
Whose responsibility is it 
to report ADRs?# 
Healthcare professionals (doctors, nurses, pharmacists) 32 
Patients 30 
Healthcare professional(s) and patients 138 
Reporting is not necessary 2 
 No response to question 4 
To whom can ADRs be 
reported?# 
Doctors 154 
Nurses 104 
Pharmacists 136 
Product manufacturers 183 
NADEMC 165 
No response to question 3 
How can ADRs be 
reported?# 
Only by post 1 
Only by telephone 6 
Only by email/website 12 
By post, telephone, email/website 121 
I do not know 65 
No response to question 1 
# More than one option could have been indicated 
 
Figure 7 shows participants’ responses regarding what type of ADRs are to be reported. Majority 
of the respondents (n=150, 72.8%) indicated that all suspected ADRs are to be reported, while 
14.6% (n=30) selected serious or life-threatening ADRs, 8.3% (n=17) selected ADRs not indicated 
on package insert, and 2.4% (n=5) selected uncommon ADRs. It is important to note that four 
respondents (1.9%) indicated that reporting of ADRs is not necessary. 
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Figure 7: Participants’ responses regarding what type of adverse drug reactions are to be 
reported 
 
4.4 Views on adverse drug reaction reporting 
The research questions that were investigated in this section include: 
• What are the views on ADR reporting? 
• Which factors may enhance or deter ADR reporting? 
 
One of the objectives of the study was to explore parents’ views on reporting ADRs. Participants’ 
views on public reporting is shown in Table 7. Majority of the participants (n=152+49+3, 99%) 
believed that reporting of ADRs by the public is important, while only one participant (0.5%) 
believed that it is not important at all. Participants were generally positive about reporting ADRs. 
All but four (2%) said that they would consider reporting ADRs in future. 
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Table 7: Participants’ views on public reporting 
Question Responses Frequency Percentage 
How important do you think it 
is for the public to report 
ADRs? 
Absolutely Essential 152 73.8% 
Very Important 49 23.8% 
Moderately Important 3 1.5% 
Not Important At All 1 0.5% 
No response to question 1 0.5% 
Would you consider reporting 
suspected ADRs in future? 
Definitely 169 82.0% 
Probably 23 11.2% 
Possibly 10 4.9% 
Probably Not 2 1.0% 
Definitely Not 1 0.5% 
No response to question 1 0.5% 
 
Another objective was to determine which factors could motivate or prevent parents from 
reporting ADRs experienced by their children or themselves. Figure 8 reflects the most frequent 
responses reported to possibly motivate participants to reporting ADRs. 
 
The most prominent positive theme that emerged from the open-ended questions was a social 
concern (n= 48). Participants were particularly concerned with helping others: “I will not want 
someone else to have a bad experience,” “I would report it so that no other child or person goes 
through it,” “So my feedback can help other parents or people.” Other factors motivating the 
reporting of ADRs included severity of the reaction (n=34), safety concerns (n=16) and ADRs 
experienced by self / family (n=14).  Less frequent responses include: product improvement, 
receiving feedback, receiving more information about the reporting process, fear/anxiety, 
increasing healthcare professional awareness, if the reaction is unexpected and if a causal 
relationship has been established. It should be noted that 35 participants (17%) did not respond to 
this question.  
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Figure 8: Motives for reporting adverse drug reactions 
 
Figure 9 presents the most frequent barriers that were identified from the responses. Almost one 
third of participants (n=67, 32.5%) indicated that nothing would prevent them from reporting 
ADRs experienced by themselves or their children. Some barriers reported by participants were 
process issues (n=35, 17%): “long hauled process of reporting”, time constraints (n=4, 1.9%): “just 
being busy and not having time to report it” and no feedback or actions taken (n=9, 4.4%): “should 
no action be taken, I would feel less motivated to report it.” Some patients indicated that they 
would be reluctant to report ADRs because the ADR was minor (n=11, 4.3%), or they were 
uncertain about whether the medicine caused the reaction (n=5, 2.4%). Less frequent barriers 
reported include forgetting, procrastination, fear of intimidation and condemnation, lack of 
awareness, lack of resources, lack of guidance from healthcare professionals, unapproachable 
medical staff, making an appointment to see a healthcare professional, a common reaction, a non-
prescription drug, recommended dose not given and informing people about complementary 
medicine use. Approximately one quarter of participants (n=53, 25.7%) did not respond to this 
question.  
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Figure 9: Barriers to reporting adverse drug reactions 
 
The opinion of the respondents regarding methods to better educate and inform the public about 
ADR reporting are reflected in Table 8. The respondents could have indicated more than one 
option. Awareness campaigns through tv, radio, etc. was chosen by the majority (n=174) as most 
appropriate, followed by patient education by healthcare professionals (n=171), information on 
product packaging/ leaflet (n=140) and published articles on ADR reporting (n=110). Other 
specific suggestions that were specified by the respondents include: internet campaigns through 
social media; verified information via online parenting forums; and awareness campaigns at 
schools for parents to attend. 
 
Table 8: Methods to educate and inform the public about reporting 
Methods Frequency* 
Patient education by healthcare professionals 171 
Awareness campaign through tv, radio, etc. 174 
Information on product packaging/leaflet 140 
Published articles on ADR reporting 110 
Other 18 
* More than one option could have been indicated 
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CHAPTER 5: 
DISCUSSION 
 
5.1 Introduction 
 
In this chapter, the principle findings of this study will be discussed in comparison to other 
literature on the same or similar topic where applicable. 
 
5.2 Principle findings 
 
The context of reporting ADRs in children is important to consider given the high incidence of 
ADRs experienced by children in South Africa. Most of the South African studies (Joubert and 
Naidoo, 2016; Terblanche, et al., 2017; Williams, 2015) investigated the knowledge and 
perceptions of healthcare professionals toward ADR reporting, however studies evaluating ADR 
reporting among parents are lacking. 
 
Studies conducted through interviews in the UK, US Australia, Canada, Netherlands, Malaysia 
and a few other countries, found that parents’ awareness of ADR reporting was low (Arnott, et al., 
2012; van Hunsel, et al., 2012). This study on the other hand, revealed that the participants were 
aware of ADRs and the importance of reporting them. Being white, having a degree and having 
private medical aid were associated with being significantly more aware of the term ADR 
compared to the other demographical variables. The findings suggest that South African parents 
are aware of what ADRs are and they recognised that it can harm people of all ages, that all types 
of medicines can cause ADRs and that reporting of ADRs can contribute to improving patient 
safety. Despite the infrequent reporting of ADRs by participants in this study, participants had 
knowledge of where to find more information on ADR reporting and surprisingly, how ADRs can 
be reported. The infrequent reporting by the public was consistent with other studies conducted in 
Saudi Arabia and the UK (Sales, et al., 2017).  
 
It is important to note that most of the participants in this study were well educated (i.e. completed 
matric or higher), employed and the clear majority had medical aid and received general medical 
services from the private sector. After conducting a study in India, Joshi, et al., (2015) found that 
participants who lived in urban areas were more aware of ADR reporting than those that lived in 
rural areas and that awareness of ADR reporting increased as education level increased. A similar 
study relating to patient knowledge in Poland, revealed that participants who lived in urban areas 
had more knowledge on ADR reporting compared to those that lived outside of the city 
(Staniszewska, et al., 2017). In a study conducted in Saudi Arabia, where a large percentage of 
participants (62.2%) were students or unemployed, it was found that patients were unaware of 
ADRs and ADR reporting (Sales, et al., 2017). 
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Several participants in this study indicated that they or their child experienced an ADR in the past, 
with the most common outcome of the ADR being a consultation with a doctor. Although ADRs 
are a concern for healthcare professionals, manufacturers and patients, the primary contributors of 
ADR reports have been healthcare professionals (Suleman, 2010). Research has shown that this 
responsibility should be shared between all parties and this was supported by most participants in 
this study, who stated that ADR reporting should neither be the healthcare professional’s nor the 
patient’s sole responsibility. This may be related to a finding from Kai’s study (1996) that 
suggested that parents were inevitably concerned about their child when they were unwell. Parents 
may feel that they have a responsibility to report ADRs to help their child or prevent similar 
occurrences in other children.  
 
As reported by Tobaiqy, et al. (2010) and Pahuja et al. (2014) in previous studies, participants 
displayed a positive attitude towards reporting ADRs. However, the results of this study provide 
evidence of under-reporting of ADRs, with more than a third (33.5%) of respondents not reporting 
it to healthcare professionals and an unsurprisingly larger number (85%) not reporting it to the 
product manufacturers. A lack of awareness has been identified as a contributing factor to under-
reporting and a study conducted by Joshi, et al., (2015) found that improving patients’ awareness 
can increase spontaneous reporting of ADRs. Although awareness was high in this study, the 
findings indicate a low participation rate in reporting ADRs, particularly to product manufacturers. 
Early research revealed that there were noteworthy differences between countries in the number 
of reports submitted from patients to product manufacturers, with the largest number of reports 
found in the USA (Talbot and Nilsson, 1998). Patient reporting to pharmaceutical manufacturers 
has increased over recent years, possibly due to the reduced time spent with physicians during 
consultations and the increased involvement of patients in their own healthcare (Fleuranceau-
Morel, 2002). 
 
A recurrent negative theme from the open-ended question was that participants were unsure of the 
reporting process. This is possibly due to a lack of knowledge, although the results indicated that 
many participants had knowledge of the reporting process or the steps to be taken. More than a 
third (35.5%) of participants answered, “I do not know” to the questions “Where you can find 
more information on ADR reporting?” and “How can ADRs be reported?” (31.6%). Perhaps, if 
the option of “I do not know” was available for other questions, more participants would have 
selected it. When asked what type of ADRs should be reported, almost one third of participants 
did not indicate “all suspected ADRs” suggesting that there is a lack of knowledge regarding ADR 
reporting. 
 
Two crucial problems affecting ADR reporting were identified in this study. These include patients 
anticipating a complex process and having insufficient knowledge about the process. Previous 
studies conducted by Arnott, et al., (2012) in the UK showed that after the aim and procedure were 
explained, parents were supportive of ADR reporting and found that the process was not 
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complicated. The findings from Arnott’s studies suggest that in order to overcome under-reporting, 
patients’ knowledge regarding ADR reporting needs to be improved. If appropriate information is 
communicated to patients, they may report ADRs more frequently, thus contributing towards 
better management of medicine safety. 
 
This study revealed multiple motives and barriers to reporting ADRs. Identifying the factors 
influencing reporting was a central step in determining measures to enhance reporting. Parents had 
altruistic motives for reporting ADRs and many were motivated by the severity of the ADR, and 
experiences by themselves or their families. The altruistic motives such as preventing similar 
experiences in others, increasing awareness and improving product safety, was consistent with 
previous research (Anderson, et al., 2011; Arnott, et al., 2012; Dweik, et al., 2017). 
 
Major barriers included time constraints, problems with the reporting process and concern that no 
actions would be taken. These results are similar to a systematic review that described barriers to 
ADR reporting conducted by Dweik et al., (2017) in several countries, including the UK, 
Netherlands, Australia, Uganda and Saudi Arabia, to determine the factors affecting patient 
reporting of ADRs. 
 
Educating the public and highlighting the valuable contribution that patients can make in 
improving medicine safety may assist in overcoming these barriers. A notable finding from this 
study was that a large number of participants indicated that nothing would prevent them from 
reporting ADRs experienced by themselves or their children. This was not consistent with the low 
participation rate in reporting as described earlier in this chapter, however, this study may have 
contributed to this positive response by increasing participants’ awareness of ADRs and ADR 
reporting. 
 
All patients should be encouraged to report suspected ADRs and it is evident that interventions are 
needed to improve the public’s knowledge regarding pharmacovigilance and ADR reporting 
procedures. The results reveal opportunities for public education through various methods such as 
awareness campaigns, published articles, and through healthcare professionals and product 
packaging. During their investigation, van Hunsel, et al. (2012) found that information about ADR 
reporting needs to be distributed using several methods in order to reach a larger audience. In Saudi 
Arabia, ADR reporting was promoted through educational campaigns and dissemination of flyers. 
Patients recommended that information can be provided through product labels and packaging as 
well as notices on regulatory authority websites (Sales, et al., 2017). Compared to previous years, 
there are now more information sources available to the public, which can be used to promote 
ADR reporting. These include health magazines, face-to-face wellness programs, radio and tv 
programs as well as the internet (Fleuranceau-Morel, 2002). 
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To summarise, the results suggest that parents were aware and willing to report ADRs, however 
uncertainty as to who reports ADRs and to whom, difficulties with ADR reporting procedures, and 
time constraints were found to affect parents’ likelihood to report, as observed in previous studies 
(Dweik, et al., 2017; Tobaiqy, et al., 2010). This study indicates that reporting of ADRs in South 
Africa may be increased if sufficient knowledge is imparted to parents.  
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CHAPTER 6: 
CONCLUSION AND RECOMMENDATIONS 
 
6.1 Introduction 
 
A global public health matter is the occurrence of ADRs in patients, particularly children. 
Reporting of ADRs by patients contributes to making safer medicines available and has been seen 
as a valuable contribution to protecting public health (Rolfes, et al., 2014). 
 
The aim of this investigation was to evaluate the awareness and knowledge in South Africa of 
parental reporting of suspected ADRs in themselves and their children. 
 
The following objectives were met: 
• To assess parents’ awareness of reporting ADRs 
• To assess the knowledge of parents on the procedures to follow when reporting ADRs 
• To explore parents’ views on reporting ADRs 
• To determine which factors could motivate or prevent parents from reporting ADRs 
experienced by their children or themselves 
 
The section to follow focuses on the highlights and conclusion of the study, as well as the study 
limitations, strengths and recommendations. 
 
6.2 Conclusion 
 
This study provides some insight into the awareness, knowledge and views of ADR reporting 
among parents in South Africa. It has provided an understanding of what parents knows about 
ADRs and ADR reporting and where there are gaps that need to be addressed. Despite the 
willingness of parents to report ADRs, their knowledge of ADR reporting was insufficient and 
could be improved. 
 
Statistically significant differences in awareness based on ethnicity, marital status, education level, 
medical aid and access to general medical services were observed. Inadequate representation was 
seen from the individuals living outside of Gauteng. This study, although limited with regard to 
participant distributions, highlighted which groups of individuals could possibly be targeted to 
increase ADR awareness and improve knowledge on the reporting process in future studies. Being 
black, coloured, a single parent, not finishing school, having no private medical aid and receiving 
general medical services from public clinics were significantly associated with being less aware 
of the term ADR compared to the other demographic variables. Future public health educational 
programs could be targeted more towards the above populations in order to raise their awareness 
on ADRs and the reporting process.   
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Reporting of ADRs by parents can assist in addressing the problem of under-reporting. As stated 
by Joshi, et al. (2015), parental reporting can be considerably increased if parents are 
knowledgeable about the reporting procedure. Greater awareness and knowledge among parents 
can play a considerable role in improving the safety data of medicines and may reduce the 
occurrence of ADRs in children and the general population. Some challenges in reporting of ADRs 
have been identified, which could be used to determine the methods of promoting patient reporting 
to adult patients and parents. Utilizing multiple methods for distributing information about ADR 
reporting, such as dissemination of flyers, education campaigns at schools or on social media, and 
inclusion of information on product packaging, in health magazines and on various websites, 
would be essential to reach a wide audience. 
 
Patients worldwide are becoming more involved in decisions regarding their healthcare and 
parents are naturally involved in the healthcare of their children. The number of ADR reports 
submitted globally by healthcare professionals and patients have continuously been increasing 
over the last few years, however in South Africa ADR reporting remains low. Therefore, it is 
essential to increase public reporting in order to address under-reporting of ADRs and to make 
safer medicines available to all.  
 
6.3 Study limitations 
 
This study had several limitations, particularly related to the study population. The questionnaire 
was only made available in English and therefore excluded participants who cannot read or 
understand English. The study methodology excluded the voice of the less literate and individuals 
in poorer communities who did not have access to internet and social media. Self-selection bias 
may have been introduced due to distribution of the survey on social media, which could have 
skewed the results of this study. The majority of participants lived in Gauteng, therefore the results 
could not be generalized to the larger population of parents in South Africa.  
 
6.4 Strengths of the study 
 
Voluntary responses were received from 206 individuals with different socio-demographic 
characteristics. By using a web-based survey, a large number of individuals could be reached if 
willing to respond and respondents could respond to the questionnaire at their chosen time and 
own pace. It was a convenient method to gather data with minimal costs. Anonymity was 
maintained through the online survey tool, which provided an opportunity for honest and 
unambiguous responses. 
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6.5 Recommendations 
 
Parental reporting of suspected ADRs in children can help identify unfamiliar ADRs and may 
contribute to better signal detection of ADRs. Various pharmacovigilance awareness programs 
should be conducted to encourage the reporting of ADRs by parents. Strategies to increase patient 
reporting should focus on frequent and feasible barriers to address. In addition to raising 
awareness, greater attention should be given to improving the public’s understanding of the 
reporting procedure, where and how to report and to also emphasize the importance of reporting 
ADRs. Letters of acknowledgement, which are provided to patients in the Netherlands, can be sent 
to patients who report ADRs in South Africa to assure patients that their voice is heard and to 
encourage further reporting (Dweik, et al., 2017). 
 
Incorporating healthcare professionals in the education campaigns may be of great benefit as they 
are usually the primary source of information for patients when they have questions or concerns 
regarding medicines. Healthcare professionals need to be informed of the benefits of patient 
reporting and reminded that patients can report ADRs on their own. Healthcare professionals can 
also play a vital role in improving patient reporting by encouraging patients to report suspected 
ADRs. 
 
More extensive research is required to evaluate the awareness, knowledge and views of ADR 
reporting by parents in other provinces, including rural areas. Special efforts should be made to 
specifically reach and educate populations identified as being less aware and to raise awareness of 
ADRs, i.e. blacks, coloureds, single parents, individuals who have not finished school, individuals 
who have no private medical aid and individuals who visit public clinics for general medical 
services. 
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Appendix 1  
Participant Informed Consent and Informational Sheet 
 
Title of research project: Evaluation of reporting all types of adverse drug reactions by parents of children 
younger than 18 years in South Africa 
 
Dear potential participant 
 
You are invited to participate in a research project, which is being conducted by Shavani Pillay for a 
Master’s degree in Pharmacy Administration and Policy Regulation at the University of the Western Cape 
as part of a mini-thesis.  
 
This study was approved by the Biomedical Science Research Ethics Committee of the University of the 
Western Cape on 8 June 2018 (Reference Number: BM/18/4/5). 
 
Purpose of the Study  
The aim of the study is to evaluate the awareness and knowledge in South Africa of parental reporting of 
suspected adverse drug reactions in their children. 
 
An adverse drug reaction can be described as a response to a drug which is harmful, and unintended, 
and which occurs at doses normally used in humans for prevention of diseases, for diagnostic 
purposes, to treat diseases or to change certain physiological function in the body. 
 
Who can take part in this study? 
Any parent (male or female) living in South Africa over the age of 18 years, parents of adopted children 
(younger than 18 years) and step children (younger than 18 years). 
 
Participation & Confidentiality 
Participation in this study is voluntary and you may decline to answer any questions without any reason or 
penalty. 
 
Your response is anonymous and will be kept confidential. The electronic filled questionnaires will be 
saved on a password protected database and the information will not be used for any other purpose apart 
from the purpose of this study. 
 
Risks 
There are no anticipated risks to taking part in this study apart from the time it will take to complete the 
questionnaire 
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Benefits and Rewards  
Your participation in the study will enable us to collect information on what the South African parent knows 
about how, when and who to report suspected adverse drug reactions in themselves and their children to.  
 
There will be no incentives for participating. 
 
If you have any questions about the research study itself, please contact Shavani Pillay  
3763728@myuwc.ac.za. 
 
Should you have any questions regarding this study and your rights as a research participant or if you wish 
to report any problems you have experienced related to the study, please contact:  
 
1. Supervisor - Michelle Viljoen:  mviljoen@uwc.ac.za, Tel +2721 9592641 
2. Director of School of Pharmacy - Prof SF Malan:  sfmalan@uwc.ac.za, Tel +2721 9593190 
3. Biomedical Science Research Ethics Committee (BMREC) 
Research Development 
Room 28 C Block New Arts Building 
University of the Western Cape 
Robert Sobukwe Road 
Bellville 
Cape Town 
7535 
Tel: +2721 9592988 
research-ethics@uwc.ac.za 
 
If you agree to participate, click on the link below which will take you to the study questionnaire. The 
questionnaire should take no longer than 15 minutes to complete. Please respond by 31 August 2018 and 
only submit your response once. 
 
https://docs.google.com/forms/d/e/1FAIpQLSeoKIHb17klgKByfkhNkB60SB-
FzAwkDD6P2bNIJRC0dfUZqw/viewform?usp=sf_link 
 
 
 
 
 
  
http://etd.uwc.ac.za/
45 
 
                                                    
Appendix 2 
Questionnaire 
 
A. Informed Consent 
 
1. The study has been explained to me in a language that I understand, and I freely and 
voluntarily agree to participate. 
Agree 
 
 
Disagree 
 
B. Inclusion/ exclusion 
 
1. Do you have children younger than 18 years old (including adopted and step children)? 
Yes 
 
 
No 
 
C. Demographics 
 
 
1. What is your gender? 
Male 
 
 
Female 
2. What is your age? 
18-30 
 
 
31-40 41-50 >50 
3. What is your ethnicity?   
Black 
 
Coloured Indian White Other  
 
 
 
please specify:  
____________ 
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4. Which province do you live in? 
Eastern 
Cape 
 
 
Free 
State 
Gauteng KwaZulu-
Natal 
Limpopo Mpumalanga North 
West 
Northern 
Cape 
Western 
Cape 
5. What is your current marital status? 
Single 
 
 
Married Divorced Separated Widowed 
6. How many children do you have (including adopted and step children)? 
0 
 
 
1 2 3 4 or more 
7. What is the highest level of education you have completed? 
Did not finish 
school 
 
 
Matric certificate Diploma Degree Other  
 
 
please specify: 
____________ 
 
8. Which of the following categories best describes your primary area of employment? 
Student 
 
 
Unemployed Automotive 
industry 
Education and 
training 
Financial services 
 
Healthcare 
 
 
 
Information 
technology 
 
 
Legal services  Wholesale and 
retail trade 
Other  
 
 
please specify: 
____________ 
 
9. Do you belong to a medical aid? 
Yes 
 
 
No 
10. Where do you go to access general medical services (doctor care, emergency health care, 
preventive health care services)? 
Private doctor 
 
 
Private nurse Pharmacy Public clinic 
 
 
http://etd.uwc.ac.za/
47 
 
D. Adverse Drug Reaction Awareness and Knowledge 
 
1. Were you aware of the term ‘adverse drug reaction’ before today? 
Yes 
 
No 
2. Which age group can be harmed from adverse drug reactions? More than one option may be 
applicable. 
Children Adults Elderly All ages I do not know 
3. What type of medication can cause adverse drug reactions? More than one option may be 
applicable. 
New medicines Over-the-counter 
(OTC) medicines 
Complementary 
medicines 
(traditional, 
herbal, etc.) 
 
 
All medicines I do not know 
4. Does the collection of information on adverse drug reactions contribute to improving patient 
safety? 
Yes 
 
No 
5. Have you or your child experienced an adverse drug reaction(s) after taking/being given 
medication? 
Almost Always 
 
 
Often Sometimes Seldom Never 
6. How did you become aware that you or your child may be experiencing an adverse drug 
reaction? 
 
 
 
7. What was the outcome of one of the adverse drug reactions? 
Admission to 
hospital 
Prolonged 
hospital stay (if 
reaction occurred 
in hospital) 
 
Visit to clinic  
 
Consultation with 
doctor 
 
Adverse drug 
reaction resolved 
on its own 
8. Describe briefly what one of the adverse drug reactions was about? 
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9. Did you ever tell your doctor/nurse/pharmacist about an adverse drug reaction you / your 
child experienced? 
Almost Always 
 
 
Often Sometimes Seldom Never 
10. Have you ever informed the product manufacturer (pharmaceutical company) of an adverse 
drug reaction? 
Almost Always 
 
 
Often Sometimes Seldom Never 
11. Where can you find more information on adverse drug reaction reporting? More than one 
option may be applicable. 
From a hospital 
 
From a pharmacy From a doctor’s 
surgery 
From a 
pharmaceutical 
company 
 
I do not know 
12. Whose responsibility is it to report adverse drug reactions? More than one option may be 
applicable. 
Doctors Nurses Pharmacists Patients/Parents Reporting is not 
necessary 
 
 
13. What type of adverse drug reactions (ADRs) should be reported? 
Serious or life-
threatening 
ADRs 
 
 
Uncommon 
ADRs 
 ADRs not 
indicated on 
package insert 
All suspected 
ADRs 
Reporting is not 
necessary 
 
 
14. To whom can adverse drug reactions be reported? More than one option may be applicable. 
 
Doctors Nurses Pharmacists Product 
manufacturers 
National Adverse 
Drug Event 
Monitoring Centre 
(a unit of the South 
African Health 
Products Regulatory 
Authority) 
 
 
15. How can adverse drug reactions be reported? More than one option may be applicable. 
Only by post 
 
 
Only by 
telephone 
 
Only by 
email/website 
By post, 
telephone, 
email/website 
 
 
I do not know 
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E. Views on Adverse Drug Reaction Reporting  
 
1. How important do you think it is for the public to report adverse drug reactions? 
Absolutely 
Essential 
 
 
Very Important Moderately 
Important 
Of Little 
Importance 
Not Important 
At All  
 
2. Would you consider reporting suspected adverse drug reactions in future? 
Definitely 
 
 
Probably Possibly Probably Not Definitely Not 
3. What would motivate you to report adverse drug reactions experienced by you and/or your 
child? 
 
 
 
4. What would prevent you from reporting adverse drug reactions experienced by you and/or 
your child? 
 
 
 
5. In your opinion, how can the public be better educated and informed about adverse drug 
reaction reporting? More than one option may be applicable. 
Patient education 
by healthcare 
professionals 
(doctor/nurse/ 
pharmacist) 
 
 
Awareness 
campaign 
through tv, radio, 
etc. 
Information on 
product 
packaging/leaflet 
 
Published articles 
on ADR reporting 
Other  
 
 
please specify:  
 
____________ 
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